A targeted immunotherapy developed by iTeos Therapeutics and GSK showed promising response rates in lung cancer patients, leading to a Phase 3 trial. The combination of a TIGIT-targeting antibody and GSK’s Jemperli increased tumor shrinkage compared to Jemperli alone, meeting the Phase 2 trial goals. Analysts had expected this success. iTeos’ CEO Michel Detheux expressed excitement about the depth of the response. This development fuels a broader debate on the validity of the target. The results are seen as a significant advancement in the treatment of lung cancer, highlighting the potential of immunotherapy in the field.
Source link
iTeos, GSK lung cancer drug shows potential, boosting TIGIT as viable target
